Advanced mast cell disease: An Italian Hematological Multicenter experience

International Journal of Hematology

Volumn 88, Issue 5, 2009, Pages 483-488

  Pagano, Livio ^a   Valentini, Caterina Giovanna ^a   Caira, Morena ^a   Rondoni, Michela ^b   Van Lint, Maria Teresa ^c   Candoni, Anna ^d   Allione, Bernardino ^e   Cattaneo, Chiara ^f   Marbello, Laura ^g   Caramatti, Cecilia ^h   Pogliani, Enrico Maria ⁱ   Iannitto, Emilio ^j   Giona, Fiorina ^k   Ferrara, Felicetto ^l   Invernizzi, Rosangela ^m   Fanci, Rosa ⁿ   Lunghi, Monia ^o   Fianchi, Luana ^a   Sanpaolo, Grazia ^p   Stefani, Pietro Maria ^q   Pulsoni, Alessandro ^k   Martinelli, Giovanni ^b   Leone, Giuseppe ^a   Musto, Pellegrino ^r   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e Ospedale di Alessandria   (Italy)

^f Divisione di Ematologia   (Italy)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ SAN GERARDO HOSPITAL   (Italy)

^j Divisione di Ematologia   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l CARDARELLI HOSPITAL   (Italy)

^m UNIVERSITY OF PAVIA   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^p CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^q OSPEDALE CA FONCELLO   (Italy)

^r REFERRAL CANCER CENTER OF BASILICATA   (Italy)

more..

Author keywords

Mast cell disease; Therapy; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; IMATINIB; PIPOBROMAN; STEM CELL FACTOR RECEPTOR; STEROID; THALIDOMIDE; TIOGUANINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; MALE; MAST CELL DISEASE; MAST CELL LEUKEMIA; MOLECULAR BIOLOGY; POINT MUTATION; REMISSION; RETROSPECTIVE STUDY; SPLEEN DISEASE; STEROID THERAPY; SYSTEMIC MASTOCYTOSIS; THROMBOCYTHEMIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOTRANSPLANTATION; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ITALY; LIVER; MASTOCYTOSIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SPLEEN; SURVIVAL RATE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; ITALY; LIVER; MALE; MASTOCYTOSIS; MIDDLE AGED; PIPERAZINES; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPLEEN; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 64249092051     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0166-4     Document Type: Article

References (33)

1. P Valent C Akin WR Sperr 2003 Diagnosis and treatment of systemic mastocytosis: state of the art Br J Haematol 122 695 717 10.1046/j.1365-2141. 2003.04575.x (Pubitemid 37100296)
2. HP Horny P Valent 2001 Diagnosis of mastocytosis: general histopathological aspects, morphological criteria and immunohistochemical findings Leuk Res 25 543 51 10.1016/S0145-2126(01)00021-2 (Pubitemid 32506761)
3. P Valent HP Horny L Escribano 2001 Diagnostic criteria and classification of mastocytosis: a consensus proposal Leuk Res 25 603 25 10.1016/S0145-2126(01) 00038-8 (Pubitemid 32506768)
4. Valent P, Metcalfe DD. Mast cells proliferative disorders: diagnosis, classification and therapy. In: O'Brien S, Teffery A, Valent P, editors. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program) 2004; p. 146-62.
5. A Pardanani 2005 Systemic mastocytosis: bone marrow pathology, classification and current therapies Acta Haematol 114 1 41 51 10.1159/000085561 (Pubitemid 40911571)
6. Valent P, Horny HP, Li Cy, et al. Mastocytosis (mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardman J, editors. World Health Organization (WHO) classification of tumors. Pathology and genetics. Tumors of haematopoietic and lymphoid tissue. Vol. 1; 2001. p. 291-302.
7. P Valent C Akin WR Sperr HP Horny DD Metcalfe 2003 Mast cell proliferative disorders: current view on variants recognized by the World Health Organization Hematol Oncol Clin North Am 17 5 1227 41 10.1016/S0889-8588(03) 00089-3 (Pubitemid 37187806)
8. A Tefferi JW Vardiman 2008 Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 22 1 14 22 10.1038/sj.leu.2404955
9. A Tefferi S Verstovsek A Pardanani 2008 How we diagnose and treat WHO-defined systemic mastocytosis in adults Haematologica 93 1 6 9 10.3324/haematol.12324
10. P Valent C Akin WR Sperr 2003 Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria Leuk Res 27 635 41 10.1016/S0145-2126(02)00168-6 (Pubitemid 36398099)
11. B Hennessy F Giles J Cortes 2004 Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience Am J Hematol 77 209 14 10.1002/ajh.20211 (Pubitemid 39430697)
12. P Casassus N Caillat-Vigneron A Martin 2002 Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients Br J Haematol 119 1090 7 10.1046/j.1365-2141.2002.03944.x (Pubitemid 35463838)
13. CH Dunphy 2005 Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes Arch Pathol Lab Med 129 2 219 22 (Pubitemid 40204802)
14. AW Hauswirth I Simonitsch-Klupp M Uffmann 2004 Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature Leuk Res 28 249 57 10.1016/S0145-2126(03)00259-5 (Pubitemid 37550059)
15. J Simon O Lortholary N Caillat-Vigneront 2004 Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature Pathol Biol (Paris) 52 5 294 9 10.1016/j.patbio.2004.04.012 (Pubitemid 38813226)
16. A Tefferi 2004 Treatment of systemic mast cell disease: beyond interferon Leuk Res 28 3 223 4 10.1016/j.leukres.2003.09.004 (Pubitemid 37550054)
17. A Tefferi CY Li JH Butterfield HC Hoagland 2001 Treatment of systemic mast-cell disease with cladribine N Engl J Med 344 4 307 9 10.1056/ NEJM200101253440415
18. A Pardanani AV Hoffbrand JH Butterfield A Tefferi 2004 Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine Leuk Res 28 127 31 10.1016/S0145-2126(03)00185-1 (Pubitemid 37492938)
19. HC Kluin-Nelemans JM Oldhoff JJ Van Doormaal 2003 Cladribine therapy for systemic mastocytosis Blood 102 13 4270 6 10.1182/blood-2003-05-1699 (Pubitemid 37494083)
20. C Akin K Brockow C D'Ambrosio 2003 Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild type or mutated forms of c-kit Exp Hematol 31 686 92 10.1016/S0301-472X(03)00112-7 (Pubitemid 36945381)
21. A Quintanas-Cardama A Aribi J Cortes FJ Giles H Kantarijan S Verstovsek 2006 Novel approaches in the treatment of systemic mastocytosis Cancer 107 7 1429 39 10.1002/cncr.22187 (Pubitemid 44546901)
22. GW Krystal 2004 Imatinib mesylate (STI571) for myeloid malignancies other than CML Leuk Res 28 Suppl 1 S53 9 10.1016/j.leukres.2003.10.003 (Pubitemid 38251499)
23. A Pardanani M Elliott T Reeder 2003 Imatinib for systemic mast-cell disease Lancet 362 9383 535 6 10.1016/S0140-6736(03)14115-3 (Pubitemid 36976719)
24. HJ Droogendijk HJC Kluin-Nelemans JJ van Doormaal AP Oranjie AA van de Loosdrecht PL van Daele 2006 Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial Cancer 7 2 345 51 10.1002/cncr.21996 (Pubitemid 44036564)
25. D Rossov-Jessen P Lovgreen Nielsen T Horn 1991 Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome Bone Marrow Transplant 8 5 413 5
26. R Nakamura S Chakrabarti C Akin 2006 A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis Bone Marrow Transplant 37 4 353 8 10.1038/sj.bmt.1705245 (Pubitemid 43250468)
27. A Spyridonidis AK Thomas H Bertz 2004 Evidence for a graft-versus-mast- cell effect after allogeneic bone marrow transplantation Bone Marrow Transplant 34 6 515 9 10.1038/sj.bmt.1704627 (Pubitemid 39264042)
28. S Verstovsek C Akim T Manshouri 2006 Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit Leuk Res 30 11 1365 70 10.1016/j.leukres.2006.04.005 (Pubitemid 44307328)
29. KV Gleixner M Mayerhofer KJ Aichberger 2006 PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects Blood 107 2 752 9 10.1182/blood-2005-07-3022 (Pubitemid 43076402)
30. NP Shah FY Lee R Luo Y Jiang M Donker C Akin 2006 Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Blood 108 1 286 91 10.1182/blood-2005-10-3969 (Pubitemid 43990640)
31. D Purtill J Cooney R Sinniah 2008 Dasatinib therapy for systemic mastocytosis: four cases Eur J Haematol 80 5 456 8 10.1111/j.1600-0609.2008. 01048.x
32. TM) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Abstract no. 3551, ASH 2007.
33. Rondoni M, Paolini S, Colarossi S, et al. Response to Dasatinib in patients with aggressive systemic mastocytosis with D816V Kit mutation. Abstract no. 3562, ASH 2007.